Journal article
PARP Inhibitors in Prostate and Urothelial Cancers
Frontiers in oncology, Vol.10, 114
02/07/2020
DOI: 10.3389/fonc.2020.00114
PMCID: PMC7020773
PMID: 32117762
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors targeting DNA repair gene mutations have shown significant clinical benefit in patients with ovarian and breast cancers. In metastatic prostate cancers, the prevalence of DNA repair gene mutations is up to 20%, and early phase studies have shown clinical activity of PARP inhibitors. Numerous clinical trials with either PARP monotherapy or in combination with other therapeutic agents are ongoing in prostate cancer. In this comprehensive review, we provide the rationale, efficacy, and safety data of PARP inhibitors in prostate as well as urothelial cancers.
Details
- Title: Subtitle
- PARP Inhibitors in Prostate and Urothelial Cancers
- Creators
- Rohan Garje - University of IowaRaju Kumar Vaddepally - Yuma Oncology CenterYousef Zakharia - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Frontiers in oncology, Vol.10, 114
- DOI
- 10.3389/fonc.2020.00114
- PMID
- 32117762
- PMCID
- PMC7020773
- NLM abbreviation
- Front Oncol
- ISSN
- 2234-943X
- eISSN
- 2234-943X
- Publisher
- Frontiers Media Sa
- Number of pages
- 9
- Grant note
- P30 CA086862 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Language
- English
- Date published
- 02/07/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548379602771
Metrics
7 Record Views